Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings

Moldovan, Christina; Weldon, Abby J.; Daher, Noha; Schneider, Louise E.; Bellinger, Denise L.; Berk, Lee; Hermé, Alyson C.; Aréchiga, Adam L.; Davis, Willie; Peters, Warren

doi:10.1002/oby.21649

Cited by 42 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug stimulates primarily the release of norepinephrine, but to lower extent also dopamine and serotonine. Depending on the dose (which is typically between 30 and 37.5 mg/d) the placebo-subtracted weight loss attributed to treatment with phentermine (30 mg/d) is in the range of 4-8 kg after 12 weeks of treatment (Kim et al, 2006;Kang et al, 2010;Moldovan et al, 2016). Phentermine is generally well tolerated with little to no abusive potential, even when used chronically for up to 21 years (Hendricks et al, 2009).…”

Section: B 24-dinitrophenolmentioning

confidence: 99%

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

et al. 2018

View full text Add to dashboard Cite

Section: B 24-dinitrophenolmentioning

confidence: 99%

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

et al. 2018

View full text Add to dashboard Cite

“…JumpstartMD weight losses were compared to those reported for other commercial programs (Weight Watchers [6,8,[11][12][13][14][31][32][33][34][35][36][37][38][39][40][41][42], Slimming World [12, 13, 15-22, 37, 43], Rosemary Conley [12,13,37,42], Biggest Losers Club [25,44,45], eDiet [46,47], Jenny Craig [23,24,33,[48][49][50], Itrim [26], Nutrisystem [9,33,[51][52][53], Medifast [28,29,[54][55][56], Health Management Resources [30,[57][58][59], Metabolic Balance Nutrition Program [27], and D...…”

Section: Comparison With Other Published Studiesmentioning

confidence: 99%

“…With one notable exception, the comparative analyses of Table 3 show that JumpstartMD patients lost greater weight than reported for other calorie-counting, food choice, and meal plans (Weight Watchers, Slimming World, Rosemary Conley, and Itrim). JumpstartMD kg weight loss was 53% greater at 12-13 weeks, 84% greater at 24-26 weeks, and 75% Meffert [27] Meffert [27] Meffert [27] Meffert [27] Collins [44] Collins [44] Collins [45] Collins [45] Collins [45] Collins [45] Gold [46] Gold [46] Baetge [33] Rock [50] Rock [49] Rock [49] Rock [50] Rock [49] Rock [49] Baetge [33] Foster [52] Figueroa [53] Moldovan [55] Coleman [28] Davis [54] Shikany [56] Coleman [28] Davis [54] Shikany [56] Coleman [29] Coleman [29] Smith [59] Smith [59] Donnelly [58] Donnelly [58] Furlow [30] Donnelly [58] Donnelly [58] Furlow [30] Fabricatore [51] Fabricatore [51] greater at 1 year than reported for other commercial caloriecounting programs for LOCF analyses and approximately 2fold greater...…”

Section: Itrimmentioning

confidence: 99%

Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults

Bourke¹,

Morton

Williams³

2020

Journal of Obesity

View full text Add to dashboard Cite

Background. Commercial weight loss programs provide valuable consumer options for those desiring support. Several commercial programs are reported to produce ≥3-fold greater weight loss than self-directed dieting. The effectiveness of JumpstartMD, a commercial pay-as-you-go program that emphasizes a low-to-very-low-carbohydrate real-food diet and optional pharmacologic treatment without prepackaged meals or meal replacement, has not previously been described. Methods. Completer and last observation carried forward (LOCF) of clinic-measured weight loss (kg) in 18,769 female and 3638 male JumpstartMD participants. Results. Completers lost (mean ± SE) 8.7 ± 0.04 kg, 9.5 ± 0.04% with 44.5 ± 0.5% achieving ≥10% weight loss at 3 months (mo, N = 14,999 completers); 11.8 ± 0.1 kg, 12.6 ± 0.1% with 66.4 ± 0.6% achieving ≥10% weight loss at 6 mo (N = 11,805); and 11.5 ± 0.2 kg, 12.0 ± 0.2% with 57.6 ± 0.9% achieving ≥10% weight loss at 12 mo (N = 8514). LOCF estimates were −6.5 ± 0.03 kg, −7.2 ± 0.03% with 27.1 ± 0.3% achieving ≥10% weight loss at 3 mo; −7.7 ± 0.04 kg, −8.5 ± 0.04% with 36.3 ± 0.3% achieving ≥10% weight loss at 6 mo; and −7.7 ± 0.1 kg, −8.4 ± 0.1% with 34.6 ± 0.3% achieving ≥10% weight loss after 12 mo. Frequent health coach meetings was a major determinant of weight loss, with women and men attending ≥75% of their weekly appointments losing 8.8 ± 0.04 and 11.9 ± 0.1 kg, respectively, after 3 mo, 13.1 ± 0.1 and 16.5 ± 0.3 kg after 6 mo, and 16.5 ± 0.3 and 19.4 ± 0.8 kg after 12 mo. Phentermine and phendimetrazine had a minor effect in women only at 1 (6.1% greater weight loss than untreated), 2 (4.1%), and 3 mo (1.2%), but treated patients showed longer enrollment than nontreated during the first 3 (females: +0.4 ± 0.01; males: +0.3 ± 0.04 mo), 6 (females: +1.1 ± 0.04; males: +1.0 ± 0.1 mo), and 12 mo (females: +2.7 ± 0.1; males: +2.4 ± 0.2 mo). JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. Conclusion. A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.

show abstract

“…Based on the studies included in the metaanalysis, the most frequent adverse drug reaction of phentermine was dry mouth and insomnia, and the incidence of the adverse reactions showed a significant increase in phentermine compared with placebo [22,[30][31][32][33][34]. In addition, cardiovascular and neurological symptoms, such as hypertension, nervousness, depression, and palpitation, were reported [22,30,[35][36][37].…”

Section: Journal Of Health Informatics and Statisticsmentioning

confidence: 99%

Meta-analysis of Change in Weight and Heart Rate for Phentermine in Obesity

Woo¹,

Jeong²

2018

J Health Info Stat

View full text Add to dashboard Cite

Obesity is defined as a body mass index (BMI) of ≥ 30 kg/m 2 [1]. In Korea, obesity is defined as BMI of 25 kg/m 2 based on the WHO Asia-Pacific perspective for Asians [2,3]. The prevalence of obesity defined by BMI >25 kg/m 2 was increased from 36.2% in 2011 to 38.9% in 2016. The prevalence rate of obesity has also been > 60% in America from 2012 [4]. Obesity needs to be considered as chronic disease [5]. It was relevant to cardiovascular diseases [6], and a report showed that approximately 40% of the mortality rate in the U.S. was due to obesity or obesity-related diseases in 2000 [7]. To reduce body weight, a weight control program that includes a dietary therapy and exercise therapy needs to be tried [8], and an appetite suppressant has been generally prescribed for obesity care [9].

show abstract

Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings

Abstract: Both phentermine combined with a meal replacement program and meal replacements alone significantly reduced body weight and food cravings; however, the addition of phentermine enhanced these effects.

Cited by 42 publications

References 36 publications

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults

Meta-analysis of Change in Weight and Heart Rate for Phentermine in Obesity

Contact Info

Product

Resources

About